In fiscal year 2019 , the leading product in terms of sales of the Japanese pharmaceutical company Takeda Pharmaceutical Co. , Ltd. was Entyvio , with a sales value of more than 347 billion Japanese yen . Entyvio is a prescription drug treating adult patients with ulcerative colitis and Crohn 's disease .
